Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2003-10-07
2008-03-11
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
Reexamination Certificate
active
07341709
ABSTRACT:
Compositions useful for labeling β-amyloid plaques and neurofibrillary tangles are provided. The compositions comprises compounds of formula (I):wherein R1is selected from the group consisting of —C(O)-alkyl, —C(O)-alkylenyl-R4, —C(O)O-alkyl, —C(O)O-alkylenyl-R4, —C═C(CN)2-alkyl, —C═C(CN)2-alkylenyl-R4,wherein R4is a radical selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl; R5is a radical selected from the group consisting of —NH2, —OH, —SH, —NH-alkyl, —NHR4, —NH-alkylenyl-R4, —O-alkyl, —O-alkylenyl-R4, —S-alkyl, and —S-alkylenyl-R4; R6is a radical selected from the group consisting of —CN, —COOH, —C(O)O-alkyl, —C(O)O-alkylenyl-R4, —C(O)-alkyl, —C(O)-alkylenyl-R4, —C(O)-halogen, —C(O)NH-alkyl, —C(O)NH-alkylenyl-R4and —C(O)NH2; R7is a radical selected from the group consisting of O, NH, and S; and R8is N, O or S; and R2is selected from the group consisting of alkyl and alkylenyl-R10and R3is alkylenyl-R10, wherein R10is selected from the group consisting of —OH, —OTs, halogen, spiperone, spiperone ketal, and spiperone-3-yl, or R2and R3together form a heterocyclic ring, optionally substituted with at least one radical selected from the group consisting of alkyl, alkoxy, OH, OTs, halogen, alkyl-R10, carbonyl, spiperone, spiperone ketal and spiperone-3-yl, and further wherein one or more of the hydrogen, halogen or carbon atoms are optionally replaced with a radiolabel.
REFERENCES:
patent: 4256727 (1981-03-01), Triplett et al.
patent: 5098996 (1992-03-01), Jacobson et al.
patent: 5227308 (1993-07-01), Jameson et al.
patent: 5609849 (1997-03-01), Kung
patent: 5614502 (1997-03-01), Flotte et al.
A. Jacobson, A.Petric, D.Hogenkamp, A. Sinur and J.R. Barrio□□1,1-Dicyano-2-[6-(dimethylamino)naphthalen-2-yl] propene (DDPN): A Solvent polarity and Viscosity Sensitive Fluorophore for Fluorescence microscopy. J. Am. Chem. Soc. 1996, 118, 5572-5579.
A.Jacobson, A.Petric, D.Hogenkamp, A.Sinur and J.R. Barrio, 1,1-dicyano-2-[6-(dimethylamino)Naphthalen-2-yl] propene (DDNP): A Solvent ploarity and Viscosity sensitive Fluorophore for Fluorescence Microscopy, J.AM.Chem.Soc 1996, 118, 5572-5579.
Jacobson, A., “1,1-Dicyano-2-[6-(dimethylamino)naphthalen-2-yl]propene (DDNP): A Solvent Polarity and Visocsity Sensitive Fluorophore for Fluorescence Microscopy”, J. Am. Chem. Soc., 1996, vol. 118, No. 2, pp. 5572-5579.
N. Alizadeh-Pasdar and E. C. Y. Li-Chan, “Application of PRODAN Fluorescent Probe to Measure Surface Hydrophobicity of Proteins Interacting with K-carrageenan” The IFT 1999 Annual Meeting, one page.
Klunk, W., et al., “Development of Small Molecule Probes for the Beta-Amyloid Protein of Alzheimer's Disease”, Neurobiology of Aging, vol. 15, No. 6, pp. 691-698, 1994.
Klunk, W., et al., “Chrysamine-G Binding to Alzheimer and Control Brain: Autospy Study of a New Amyloid Probe”, Neurobiology of Aging, vol. 16, No. 4, pp. 541-548, 1993.
Dezutter, et al., “Preparation of99mTc-N2S2Conjugates of Chrysamine G, Potential Probes for the Beta-Amyloid Protein of Alzheimer's Disease,” Journal of Labelled Compounds and Radiopharmaceuticals J. Labelled Cpd. Radiopharm. 42, (1999) 309-324.
Griffiths, P.D., et al., “Receptor Changes in the Neocortex of Post-Mortem Tissue in Parkinson's Disease and Alzheimer's Disease”, Dementia, vol. 3, (1992) pp. 239-246.
Han, et al., “Technetium Complexes for the Quantitation of Brain Amyloid,” J. Am. Chem. Soc. 1996, 118, 4506-4507.
Huang, et al., “Neuroreceptor Assay with Positron Emission Tomography: Equilibrium Versus Dynamic Approaches,” Journal of Cerebral Blood Flow and Metabolism (1986) 6:515-521.
Imamura, et al., “Regional Cerebral Glucose Metabolism in Dementia with Lewy Bodies and Alzheimer's Disease: a Comparative Study Using Positron Emission Tomography,” Neuroscience Letters 235 (1997) 49-52.
Klunk, et al., “Development of Small Molecule Probes for the Beta-Amyloid Protein of Alzheimer's Disease,” Neurobiology of Aging, vol. 15, No. 6, (1994), pp. 691-698.
Majocha, et al., “Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy,” The Journal of Nuclear Medicine, vol. 33, No. 12, Dec. 1992, pp. 2184-2189.
Merlini, et al., “Interaction of the Anthracycline 4'-iodo-4'-deoxydoxorubicin with Amyloid Fibrils: Inhibition of Amyloidogenesis,” Proc. Natl. Acad. Sci. USA, vol. 92, Mar. 1995, pp. 2959-2963.
Mielke, et al., “Regional Cerebral Glucose Metabolism and Postmortem Pathology in Alzheimer's Disease,” Acta Neuropathol (1996) 91:174-179.
Moryś, et al., “The Second Layer Neurones of the Entorhinal Cortex and the Perforant Path in Physiological Ageing and Alzheimer's Disease,” Acta Neurobiol. Exp. (1994) 54:47-53.
Naiki, et al., “Fluorometric Determination of Amyloid Fibrils in Vitro Using the Fluorescent Dye, Thioflavine T,” Analytical Biochemistry 177 (1989) 244-249.
Price, et al., “Tangles and Plaques in Nondemented Aging and “Preclinical” Alzheimer's Disease,” Ann Neurol (1999) 45:358-368.
Saito, et al., “Vector-mediated Delivery of125I-Labeled β-amyloid Peptide Aβ1-40Through the Blood-brain Barrier and Binding to Alzheimer Disease Amyloid of the Aβ1-40/ Vector Complex,” Proc. Natl. Acad. Sci. USA, vol. 92, Oct. 1995, pp. 10227-10231.
Salmon, et al., “Differential Diagnosis of (Alzheimer's) Disease with PET,” The Journal of Nuclear Medicine, vol. 35, No. 3, Mar. 1994 pp. 391-398.
Tubis, et al., “The Preparation and Use of Radioiodinated Congo Red in Detecting Amyloidosis,” Journal of the American Pharmaceutical Association, vol. 49, No. 7, Jul. 1960. pp. 422-425.
Barrio Jorge R.
Cole Gregory M.
Huang Sung-Cheng
Petric Andrej
Satyamurthy Nagichettiar
Christie Parker & Hale, LLP.
Hartley Michael G.
Regents of University of California
Samala Jagadishwar
LandOfFree
Compositions for labeling β-amyloid plaques and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for labeling β-amyloid plaques and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for labeling β-amyloid plaques and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3978972